Immunotherapy and Endothelin Receptor Antagonists Improve Overall Survival in CRPC

Researchers reviewed published clinical trials in order to summarize the results of immunotherapy and endothelin receptor antagonists for the treatment of castration-resistant prostate cancer (CRPC). They found that both types of treatment improve overall survival, but do not significantly improve progression-free survival or time to disease progression. The researchers feel that further studies are warranted.


Aberrant BAF57 Signaling Facilitates Pro-metastatic Phenotypes

“BAF57, a component of the SWI/SNF chromatin-remodeling complex conglomerate, modulates androgen receptor (AR) activity to promote prostate cancer (PCa). However, the molecular consequences of tumor-associated BAF57 expression have remained undefined in advanced disease such as castration resistant prostate cancer (CRPC) and/or metastasis…The findings herein, identifying tumor-associated BAF57 perturbation as a means to bypass androgen signaling events that facilitate novel pro-metastatic phenotypes, link BAF57 upregulation to tumor dissemination. These data thereby establish BAF57 as a putative marker of metastatic potential that could be leveraged for therapeutic intervention.”


Lessons from in-vivo models of castration-resistant prostate cancer

Significant progress has been made in the understanding of AR-dependent and AR-independent mechanisms involved in the development of CRPC. This may lead to identification of new therapeutic targets and improved therapy.


Pre-Chemo Abiraterone + Prednisone Combo Proves Effective for CRPC

The FDA recently approved a combination of two drugs—abiraterone and the steroid prednisone—for the treatment of castration-resistant prostate cancer (CRPC) in patients who have previously been treated with chemotherapy. Scientists are now testing whether the combination treatment is beneficial for patients who have not been treated with chemotherapy. Interim results indicate that the treatment doubles progression-free survival and increases overall survival from 30.1 months to 35.3 months.


Researchers Review New Treatments for Advanced Prostate Cancer and Their Cost Implications

Advanced prostate cancer patients used to be treated with palliative chemotherapy that did not improve survival. But in the past decade, researchers have introduced several new therapies for castration-resistant prostate cancer (CRPC) and related complications. These drugs include cabazitaxel (Jevtana), abiraterone acetate (Zytiga), enzalutamide (Xtandi), sipuleucel-T (Provenge), radium-223, and denosumab (Xgeva or Prolia). Two researchers recently performed a cost-benefit analysis on these new therapies. They say that costs will come down as treatment strategies—including precisely timed combinations of drugs—are refined to minimize progression and side effects.


FDA Gives Radium-223 Priority Review Status

Radium Ra 223 Dichloride will be considered as a treatment for patients who have castration-resistant prostate cancer with bone metastases under the FDA’s priority review program. The filing is based on the 922 patient phase III ALSYMPCA trial, of radium-223 plus current standard of care, or placebo plus current standard of care.


Denosumab Outshines Zoledronic Acid in Advanced Prostate Cancer

A phase III study evaluated two osteoporosis drugs, denosumab and zoledronic acid, for the treatment of skeletal problems in patients with bone metastases in castration-resistant prostate cancer (CRPC). The average time to first bone-related adverse event was 20.7 months with denosumab and 17.1 months with zoledronic acid, suggesting that denosumab was more effective in this group.

Primary source: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62344-6/fulltext